Current and historical daily PE Ratio for Chromocell Therapeutics Corp (
) from 2024 to Jun 22 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Chromocell Therapeutics stock (CHRO) PE ratio as of Jun 22 2024 is 0.
More Details
Chromocell Therapeutics Corp (CHRO) PE Ratio (TTM) Chart
Chromocell Therapeutics Corp (CHRO) PE Ratio (TTM) Historical Data
View and export this data going back to 2024. Start your Free Trial
Total 88
- 1
| Chromocell Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-22 | At Loss | 2024-04-19 | At Loss |
| 2024-06-21 | At Loss | 2024-04-18 | At Loss |
| 2024-06-20 | At Loss | 2024-04-17 | At Loss |
| 2024-06-18 | At Loss | 2024-04-16 | At Loss |
| 2024-06-17 | At Loss | 2024-04-15 | At Loss |
| 2024-06-14 | At Loss | 2024-04-12 | At Loss |
| 2024-06-13 | At Loss | 2024-04-11 | At Loss |
| 2024-06-12 | At Loss | 2024-04-10 | At Loss |
| 2024-06-11 | At Loss | 2024-04-09 | At Loss |
| 2024-06-10 | At Loss | 2024-04-08 | At Loss |
| 2024-06-07 | At Loss | 2024-04-05 | At Loss |
| 2024-06-06 | At Loss | 2024-04-04 | At Loss |
| 2024-06-05 | At Loss | 2024-04-03 | At Loss |
| 2024-06-04 | At Loss | 2024-04-02 | At Loss |
| 2024-06-03 | At Loss | 2024-04-01 | At Loss |
| 2024-05-31 | At Loss | 2024-03-28 | At Loss |
| 2024-05-30 | At Loss | 2024-03-27 | At Loss |
| 2024-05-29 | At Loss | 2024-03-26 | At Loss |
| 2024-05-28 | At Loss | 2024-03-25 | At Loss |
| 2024-05-24 | At Loss | 2024-03-22 | At Loss |
| 2024-05-23 | At Loss | 2024-03-21 | At Loss |
| 2024-05-22 | At Loss | 2024-03-20 | At Loss |
| 2024-05-21 | At Loss | 2024-03-19 | At Loss |
| 2024-05-20 | At Loss | 2024-03-18 | At Loss |
| 2024-05-17 | At Loss | 2024-03-15 | At Loss |
| 2024-05-16 | At Loss | 2024-03-14 | At Loss |
| 2024-05-15 | At Loss | 2024-03-13 | At Loss |
| 2024-05-14 | At Loss | 2024-03-12 | At Loss |
| 2024-05-13 | At Loss | 2024-03-11 | At Loss |
| 2024-05-10 | At Loss | 2024-03-08 | At Loss |
| 2024-05-09 | At Loss | 2024-03-07 | At Loss |
| 2024-05-08 | At Loss | 2024-03-06 | At Loss |
| 2024-05-07 | At Loss | 2024-03-05 | At Loss |
| 2024-05-06 | At Loss | 2024-03-04 | At Loss |
| 2024-05-03 | At Loss | 2024-03-01 | At Loss |
| 2024-05-02 | At Loss | 2024-02-29 | At Loss |
| 2024-05-01 | At Loss | 2024-02-28 | At Loss |
| 2024-04-30 | At Loss | 2024-02-27 | At Loss |
| 2024-04-29 | At Loss | 2024-02-26 | At Loss |
| 2024-04-26 | At Loss | 2024-02-23 | At Loss |
| 2024-04-25 | At Loss | 2024-02-22 | At Loss |
| 2024-04-24 | At Loss | 2024-02-21 | At Loss |
| 2024-04-23 | At Loss | 2024-02-20 | At Loss |
| 2024-04-22 | At Loss | 2024-02-16 | At Loss |
Chromocell Therapeutics Corp (CHRO) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Chromocell Therapeutics Corp
NAICS : 541713
SIC : 8731
ISIN : US1711261057
Description
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers